This article refers to 'Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies' by A. Aimo et al., published in this issue on pages xxx.doi:10.1002/ejhf.2685Christian.NitscheDivision of Cardiology, Medical University of Vienna, Vienna, ...
The group with the shorter survival was older and had a significantly higher proportion of patients with cardiac amyloidosis. Age, performance status, cardiac involvement, and the number of organs involved all independently predicted survival.7 Thus, comparison of outcomes across phase 2 studies is ...
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol 2010; 85: 757–759. Article CAS Google Scholar Tapan U, Seldin DC, Finn KT, Fennessey S, Shelton A,...
While the naturally occurring or "wild type" transthyretin protein is prone to aggregate in older people causingcardiac disease, a variety of destabilizing mutations lead either to a primary cardiomyopathy or to early onset forms of polyneuropathy, known as TTR familial amyloid polyneuropathy, affecting...
Record review of 1,068 consecutive cases of nontraumatic out-of-hospital cardiac arrest. Memphis, Tennessee, a city of more than 600,000 with roughly ... D Brookoff,AL Kellermann,BB Hackman,... - 《Annals of Emergency Medicine》 被引量: 284发表: 1994年 ...
Piper C, Butz T, Farr M, Faber L, Oldenburg O, Horstkotte D. How to diagnose cardiac amyloidosis early: impact of ECG, tissue Doppler echocardiography, and myocardial biopsy. Amyloid. 2010;17(1):1–9.Piper C, Butz T, Farr M, et al. How to diagnose cardiac amyloidosis early: impact...
How to image cardiac amyloidosis. Circ Cardiovasc Imaging 2014; 7: 552-562.Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloi- dosis. Circ Cardiovasc Imaging 2014;7:552-62. doi:10.1161/ CIRCIMAGING.113.001396.Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloidosis. ...
When and how do patients with cardiac amyloidosis die?Felix EscherM SenonerJakob DoerlerGerhard Poelzl
Cardiac amyloidosis (CA) is one of the most rapidly progressive forms of heart disease, with a median survival from diagnosis, if untreated, ranging from <6 months for light chain amyloidosis to 3 to 5 years for transthyretin amyloidosis. Early diagnosis and accurate typing of CA are necessary...
How to Identify Transthyretin Cardiac Amyloidosis at an Early Stagedoi:10.2169/internalmedicine.5505-20Yasuhiro IzumiyaHiroya HayashiHirotoshi IshikawaAtsushi ShibataMinoru YoshiyamaThe Japanese Society of Internal Medicine